行情

VNDA

VNDA

万达生物制药
NASDAQ

实时行情|Nasdaq Last Sale

9.16
-0.19
-2.03%
盘后: 9.16 0 0.00% 16:56 03/27 EDT
开盘
9.10
昨收
9.35
最高
9.34
最低
8.66
成交量
51.81万
成交额
--
52周最高
18.98
52周最低
7.12
市值
4.91亿
市盈率(TTM)
4.326
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测VNDA价格均价为15.00,最高价位25.00,最低价为7.00。

EPS

VNDA 新闻

更多
  • Healthcare And Biotechnology Dashboard - Update
  • Seeking Alpha - Article · 4天前
  • Vanda Pharmaceuticals hits another snag with FDA
  • American City Business Journals · 03/19 16:59
  • Top Biotech Stocks for Q2 2020
  • Investopedia · 03/18 19:29
  • Vanda not quite there with U.S. application for expanded use of Hetlioz
  • Seeking Alpha - Article · 03/16 13:04

所属板块

生物技术和医学研究
-2.44%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

VNDA 简况

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
展开

微牛提供Vanda Pharmaceuticals Inc.(NASDAQ-VNDA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的VNDA股票新闻,以帮助您做出投资决策。